Osteoporosis medications lower fracture risk in one of two ways: they slow bone breakdown, or they stimulate new bone formation. In US practice that means five approved groups, including bisphosphonates, the RANKL inhibitor denosumab, parathyroid hormone (PTH) analogs, the sclerostin inhibitor romosozumab, and estrogen-related agents such as the selective estrogen receptor modulator raloxifene. Selection turns on fracture risk, kidney function, dental status, cardiovascular history, and whether the patient can stay on therapy without gaps.
Why it matters: Several of these drugs carry boxed warnings or rebound risks that make the follow-up plan as important as the first dose.
The Short Version
- Two mechanisms: antiresorptive agents slow bone loss; anabolic agents build bone.
- Risk drives choice: very high fracture risk often favors starting with an anabolic agent.
- Gaps are dangerous: denosumab requires a planned follow-on antiresorptive.
- Labels differ: renal cutoffs, cardiovascular exclusions, and storage rules are agent-specific.
What Are Osteoporosis Medications? Antiresorptive Versus Anabolic
Osteoporosis medications are prescription therapies that reduce fracture risk by changing bone remodeling. Antiresorptive drugs suppress osteoclast activity, so less bone is removed and mineral density stabilizes or rises slowly. Anabolic drugs stimulate osteoblasts, adding new bone and improving microarchitecture. Calcium and vitamin D support both pathways but are adjuncts, not treatments on their own.
The distinction is practical, not academic. Antiresorptives work best as long-term maintenance and can usually be continued or paused on a schedule. Anabolic courses are time-limited by labeling and must be followed by an antiresorptive, or the gains fade. Romosozumab sits between the two: it increases formation and reduces resorption during a fixed course.
Where adjuncts fit
Most trials of these drugs enrolled patients who were calcium and vitamin D replete. Correcting deficiency before starting is part of the protocol, not an optional extra. That is especially true for denosumab and intravenous bisphosphonates, where hypocalcemia (low blood calcium) can become clinically significant.
The Main Drug Classes Used in US Practice
Each class has a dominant safety signal that shapes patient selection. The table summarizes the agents clinics encounter most often. Routes and intervals come from US labeling; always confirm the current prescribing information before use.
| Class | Representative agents | Route and interval | Selection-limiting safety points |
|---|---|---|---|
| Oral bisphosphonates | Alendronate, risedronate, ibandronate | Oral, weekly or monthly (daily forms exist) | Upper GI irritation; strict upright dosing with plain water; renal thresholds |
| Intravenous bisphosphonates | Zoledronic acid, ibandronate IV | IV, yearly or quarterly by agent | Acute-phase reaction after first infusion; renal contraindications; hydration needed |
| RANKL inhibitor | Denosumab | Subcutaneous, every 6 months | Boxed warning for severe hypocalcemia in advanced CKD; rebound vertebral fracture if stopped without follow-on therapy |
| PTH and PTHrP analogs | Teriparatide, abaloparatide | Subcutaneous, daily; course limited by labeling | Hypercalcemia, orthostatic hypotension early in therapy; cautions in patients at baseline osteosarcoma risk |
| Sclerostin inhibitor | Romosozumab | Subcutaneous, monthly for 12 doses | Boxed warning for myocardial infarction, stroke, and cardiovascular death; not started within one year of MI or stroke |
| Estrogen-related agents | Raloxifene, menopausal hormone therapy | Oral, daily | Raloxifene boxed warning for venous thromboembolism and fatal stroke; vertebral fracture benefit mainly |
Calcitonin remains approved but is used infrequently because fracture-risk reduction is modest compared with other options. Denosumab biosimilars have entered the US market, so clinics should confirm which product and presentation a given order reflects before documenting administration.
Patient Selection and Contraindications
Treatment candidacy usually rests on three findings: a prior hip or vertebral fragility fracture, a bone mineral density T-score of -2.5 or lower at the spine, femoral neck, or total hip, or elevated calculated fracture probability in low bone mass. US guidance commonly uses FRAX thresholds of 3 percent for 10-year hip fracture or 20 percent for major osteoporotic fracture. Clinician guidance from the Bone Health and Osteoporosis Foundation sets out those thresholds in detail.
Before any first dose, secondary causes deserve a look. A typical workup includes complete blood count, comprehensive metabolic panel, 25-hydroxyvitamin D, intact PTH, thyroid-stimulating hormone, and 24-hour urine calcium, with protein electrophoresis when myeloma is a concern. Treating an unrecognized cause changes the plan.
Key exclusions recur across the classes:
- Uncorrected hypocalcemia: a contraindication for bisphosphonates and denosumab.
- Reduced renal clearance: bisphosphonates are generally not recommended below roughly 30 to 35 mL/min, with the exact cutoff set by each label.
- Recent cardiovascular event: romosozumab is not initiated within a year of MI or stroke.
- Esophageal abnormalities: achalasia or stricture, or inability to sit upright, rules out oral bisphosphonates.
- Thrombotic history: prior venous thromboembolism argues against raloxifene.
Sequencing, Duration, and the Problem of Treatment Gaps
Order matters. In patients at very high fracture risk, consensus guidance favors starting with an anabolic agent and then consolidating with an antiresorptive. The reverse order blunts the anabolic response, particularly when romosozumab follows prior bisphosphonate exposure. Anabolic courses are finite by design, so the transition drug should be chosen before the course ends.
Bisphosphonates are the main class where a planned pause is reasonable. After about three to five years of oral therapy, or roughly three years of annual infusion, patients at moderate risk may be reassessed for a drug holiday, while those at high risk often continue longer. Skeletal retention of bisphosphonate is what makes that pause possible.
Denosumab behaves differently. Its effect does not persist after dosing stops, and delayed or discontinued doses have been associated with rapid bone loss and multiple vertebral fractures. Clinics that administer it should treat the six-month interval as a recall obligation, with a documented plan for follow-on bisphosphonate therapy if treatment ends.
Safety Signals and When to Escalate
Three warnings should be visible to anyone administering these drugs. First, denosumab carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, including those on dialysis; the FDA’s drug safety communications are published and updated here. Second, romosozumab carries a boxed warning for myocardial infarction, stroke, and cardiovascular death. Third, raloxifene carries a boxed warning for venous thromboembolism and fatal stroke.
Recognition and referral
- Hypocalcemia: perioral numbness, muscle cramps, tetany, seizures, or QT prolongation call for urgent evaluation and electrolyte testing.
- Atypical femoral fracture: new thigh or groin pain during long-term antiresorptive therapy warrants femoral imaging, usually bilateral, and reassessment of continued therapy.
- Osteonecrosis of the jaw: exposed bone or a nonhealing extraction site should be referred to oral and maxillofacial surgery.
- Acute-phase reaction: fever, myalgia, and arthralgia within days of a first infusion are usually self-limited, but persistent or severe symptoms need review.
- Cardiovascular symptoms: chest pain or neurologic deficits during therapy require emergency assessment, not a routine follow-up visit.
A dental evaluation before starting intravenous bisphosphonate or denosumab is widely recommended, particularly for patients with active dental disease or planned extractions. It does not eliminate risk, but it removes the most avoidable trigger.
Monitoring, Labs, and Follow-Up Imaging
Monitoring answers two questions: is the drug being taken, and is the skeleton responding. Dual-energy X-ray absorptiometry (DXA) is usually repeated one to two years after starting therapy, then at intervals based on response and risk. Repeat scans should use the same machine where possible, because cross-device comparisons are unreliable.
Laboratory review is agent-specific. Serum calcium and renal function are checked before each denosumab or zoledronic acid dose, and 25-hydroxyvitamin D is confirmed adequate. Bone turnover markers such as serum CTX or P1NP are optional and are most useful for checking adherence or confirming a biologic response, not for diagnosing osteoporosis.
Adherence is the quietest failure point. Oral bisphosphonate persistence at one year is poor in routine practice, and a fracture during apparently adequate therapy should prompt an adherence check, a secondary-cause review, and consideration of a different class rather than automatic escalation.
Handling, Cold Chain, and Procurement Notes
Most injectable agents in this group are refrigerated biologics or peptides. Denosumab, teriparatide, abaloparatide, and romosozumab are stored at 2 to 8 degrees Celsius in the original carton, protected from light, and not frozen. Prefilled syringes and pens are allowed to reach room temperature before injection, and some pens have defined in-use room-temperature windows. Follow the specific label rather than a general clinic rule. Zoledronic acid in ready-to-infuse bottles is stored at controlled room temperature.
For clinic operations, a workable sequence is: verify the prescription and indication, confirm labs and dental status, order and receive with temperature documentation, log lot and expiration, administer and record site and date, then schedule the next dose before the patient leaves. Cold-chain excursions should be documented and the product quarantined pending review.
On the supply side, these products reach clinics through specialty distribution, buy-and-bill arrangements, or wholesale channels. Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013. Whatever the channel, keep the current US prescribing information on hand; DailyMed publishes current labeling for US products.
Clinic Checklist Before the First Dose
- Confirm the indication: fracture history, T-score, or calculated risk documented.
- Rule out secondary causes: labs reviewed and abnormalities addressed.
- Check calcium and vitamin D: corrected before antiresorptive therapy.
- Verify renal function: matched against the specific agent’s label.
- Screen cardiovascular and thrombotic history: relevant to romosozumab and raloxifene.
- Arrange dental review: before intravenous bisphosphonate or denosumab where indicated.
- Set the recall interval: next dose and next DXA booked, with a documented exit plan.
Used well, this class of drugs is one of the better-evidenced interventions in preventive medicine. Most of the avoidable harm comes from gaps, missed labs, and unplanned discontinuation rather than from the drugs themselves. Keep the plan written, the recall date firm, and the labeling close at hand.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.







